Coccidioides

Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update

Retrieved on: 
Donnerstag, Mai 9, 2024
Brain, Coccidioides, Inflammation, Aspergillosis, Amphotericin B, Lecture, Lower respiratory tract infection, Safety, Skin, Antimicrobial, Conference call, Abstract, Fungal infection, Survival, Partnership, Cell, Research, Hepatocellular carcinoma, BioNTech, Patient, Gene, Society, Histoplasmosis, Lung, Malignancy, Toxicity, Manuscript, Standard of care, Infection, Annual general meeting, Platinum, LNC, Pharmaceutical industry

BEDMINSTER, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, reports financial results for the three months ending March 31, 2024 and provides a business update.

Key Points: 
  • Conference call begins at 4:30 p.m. Eastern time today
    BEDMINSTER, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, reports financial results for the three months ending March 31, 2024 and provides a business update.
  • “We are highly encouraged by results from in vivo studies demonstrating a substantial reduction in the well-recognized toxicity of IV-docetaxel.
  • Subsequent to the close of the quarter, in April the Company raised gross proceeds of $10.0 million through a registered direct offering.
  • The live webcast will be accessible on the Investors section of the company’s website and archived for 90 days.

Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update

Retrieved on: 
Mittwoch, März 27, 2024
Malignancy, Colitis, Survival, BioNTech, Patient, Lung, City, Standard of care, Quality of life, Fungal infection, Aspergillosis, Nationwide, Clinical trial, Bone marrow, Melanoma, Aspergillus fumigatus, Therapy, Human, Psoriasis, Partnership, World Health Organization, Coccidioides, Safety, Clutch (eggs), University, Kidney, Amphotericin B, Neoplasm, Research, Data monitoring committee, Infection, Skin, Vanderbilt University Medical Center, Hospital, Immunodeficiency, FDA, Critical, Element, Toxicity, IL-17A, Brain, Conference call, Conference, Johns Hopkins, Nephrotoxicity, Docetaxel, Serum, Inflammation, Mouse, Mortality, Fusarium, Bangladesh Technical Education Board, Pharmaceutical industry

BEDMINSTER, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, reports 2023 financial results and provides a business update.

Key Points: 
  • Aspergillus fumigatus is also included in the FDA qualified designation list of pathogens that pose a serious and life-threatening risk.
  • Revenue for 2023 was $1.1 million, which was generated from the Company’s research collaborations with BioNTech SE and Genentech Inc.
  • Cash, cash equivalents and marketable securities as of December 31, 2023 were $13.8 million compared with $28.8 million as of December 31, 2022.
  • Matinas will host a conference call and webcast today beginning at 4:30 p.m. Eastern time.

Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution

Retrieved on: 
Montag, Februar 26, 2024
Infection, Bangladesh Technical Education Board, Division, Amphotericin B, Palliative care, Recurrence, University, Doctor of Philosophy, Malignancy, Nationwide, Physician, City, Azole, Hospital, Cryptococcosis, Nephrotoxicity, Skin, Aspergillosis, Fusarium, Lung, Fungal infection, Johns Hopkins, Vanderbilt University Medical Center, LNC, Coccidioides, Patient, Coccidioidomycosis, Histoplasmosis, Brain, Pharmaceutical industry

BEDMINSTER, N.J., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, today provided an update from its ongoing Compassionate/Expanded Use Access Program (the “Program”) with MAT2203, the Company’s proprietary, LNC-delivered oral formulation of the broad-spectrum antifungal drug amphotericin B.

Key Points: 
  • Treatment with MAT2203 was well tolerated and led to favorable clinical and radiological response and we did not observe any renal toxicity.
  • 5 additional patients have shown objective improvement in clinical markers and are continuing treatment with MAT2203 as planned.
  • 2 patients transitioned to palliative care shortly after starting therapy with MAT2203 because of unanticipated progression of their malignant disease.
  • “We continue to be excited about the ongoing, consistent positive clinical impact of MAT2203, seen in these extremely ill patients,” said Theresa Matkovits, PhD, Chief Development Officer at Matinas .

NFL Star Rob Gronkowski and Anivive Lifesciences Join Congressional Leaders on Capitol Hill to Combat the Rising Threat of Valley Fever

Retrieved on: 
Dienstag, Dezember 19, 2023
Spore, Pet, Risk, Gronk, Infection, Research, Fungus, FDA, University, Vaccine, Disease, Health, PRV, Human, Congress, Inhalation, Dog, Coccidioidomycosis, Animal, Fungal infection, Climate change, Tropical disease, NFL, Public, Super Bowl, USDA, Coccidioides, Veterinarian, Military personnel, Southwestern United States, Soil

WASHINGTON, Dec. 19, 2023 /PRNewswire/ -- On Capitol Hill last Tuesday, NFL Icon and 4-time Super Bowl Champion Rob Gronkowski and Senators Mark Kelly, Kyrsten Sinema, Markwayne Mullin, and Representative David Schweikert led an event focused squarely on the rising challenge of Valley Fever. Intensified by climate change, this fungal infection is not only a burgeoning public health concern in the American Southwest but also a significant economic burden, costing the U.S. healthcare system an estimated $3.9 billion annually.

Key Points: 
  • - Capitol Hill puts Valley fever in the spotlight just in time as Anivive's canine vaccine is under regulatory review.
  • - Congress introduced 4 bills that aim to fast-track the FDA review of Valley fever solutions and authorize $500 million to support fungal disease initiatives.
  • WASHINGTON, Dec. 19, 2023 /PRNewswire/ -- On Capitol Hill last Tuesday, NFL Icon and 4-time Super Bowl Champion Rob Gronkowski and Senators Mark Kelly, Kyrsten Sinema, Markwayne Mullin, and Representative David Schweikert led an event focused squarely on the rising challenge of Valley Fever.
  • Valley Fever, a serious fungal infection caused by the soil-dwelling Coccidioides, results in tens of thousands of human cases each year.

F2G and Shionogi Present Full Data Set from Pivotal Phase 2b Study at Trends in Medical Mycology (TIMM) 2023 Demonstrating Positive Therapeutic Responses in Patients with Invasive Fungal Infections Treated with Oral Olorofim

Retrieved on: 
Samstag, Oktober 21, 2023
Standard of care, TIMM, Immunodeficiency, Congress, MD, EORTC, Doctor of Philosophy, Fungus, Research, Coccidioidomycosis, DRC, Shionogi, UZ Leuven, Hematology, OASIS, Scopulariopsis, World Health Organization, Risk, Antifungal, Medical Mycology, ACM, Fungal infection, Goodyear F2G Corsair, Patient, Infection, Birth control, Pharmaceutical industry, Coccidioides, F2G

These findings were submitted as a late breaking abstract and exceptionally accepted for an oral presentation during the 11th Congress on Trends in Medical Mycology (TIMM) 2023 held in Athens, Greece, from 20-23 October 2023.

Key Points: 
  • These findings were submitted as a late breaking abstract and exceptionally accepted for an oral presentation during the 11th Congress on Trends in Medical Mycology (TIMM) 2023 held in Athens, Greece, from 20-23 October 2023.
  • F2G and Shionogi & Co., Ltd. are collaborating to develop and commercialise olorofim, bringing the novel antifungal therapy to patients with invasive fungal infections.
  • F2G has commercial responsibility for olorofim in North America, and Shionogi has commercial responsibility for olorofim in Europe and Asia Pacific.
  • F2G and Shionogi are currently enrolling patients with invasive aspergillosis in a global Phase 3 study (OASIS) to compare treatment with olorofim versus AmBisome® followed by standard of care ( NCT05101187 ).

Applied BioCode Announces the Launch of the Fungal Panel Assay for Research Use

Retrieved on: 
Montag, Juni 12, 2023
Research, Technology, Infectious Diseases, Other Technology, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, EUA, UDM, Hair, Infection, Bachelor, BMB, Allergy, Workflow, RPP, Culture, SARS-CoV-2, Software, Pneumocystis jirovecii, COVID-19, Eye, Aspergillus, Histoplasma capsulatum, CE marking, PCR, Nomenclature codes, Immunochemistry, Emergency Use Authorization, Federal Food, Drug, and Cosmetic Act, Panel, Coccidioides, RSV, RUO, Patient, Laboratory, Autoimmune disease, Molecular Probes, IVD, Growth, GPP, Immunodeficiency, Diagnosis, FDA, Mucor, Virus, Vaccine, Rhizopus, Applied Spectral Imaging, Rhizomucor, Fusarium, Cunninghamella, Cryptococcus

The Fungal Panel Assay was developed to detect the most common agents of invasive fungal infections (IFIs) particularly in lower respiratory samples.

Key Points: 
  • The Fungal Panel Assay was developed to detect the most common agents of invasive fungal infections (IFIs) particularly in lower respiratory samples.
  • Applied BioCode’s Fungal Panel is intended for research use only and may be used in infectious disease research or pharmaceutical development.
  • “Applied BioCode is thrilled to announce our first release of an RUO panel under our new product strategy.
  • Applied BioCode, Inc. has also been granted an Emergency Use Authorization (EUA) from the U.S. FDA for its BioCode® SARS-CoV-2 Flu Plus Assay ⱡ, BioCode® SARS-CoV-2 Assay*, and an additional EUA for Pooled COVID-19 Testing*.

F2G Announces FDA Filing Acceptance of New Drug Application for Olorofim for the Treatment of Invasive Fungal Infections

Retrieved on: 
Montag, Dezember 19, 2022
Fungus, Disease, PDUFA, Scopulariopsis, Food, Mycosis, MD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Antibiotic, File, NDA, DHODH, Patient, Mortality, Aspergillosis, Prescription Drug User Fee Act, FDA, Breakthrough therapy, Coccidioides, New Drug Application, Pharmaceutical industry, F2G

F2G has requested approval of the NDA under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD pathway) for a limited, well-defined population with invasive fungal infections and limited or no treatment options.

Key Points: 
  • F2G has requested approval of the NDA under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD pathway) for a limited, well-defined population with invasive fungal infections and limited or no treatment options.
  • Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a target action date of June 17, 2023.
  • “Invasive fungal infections cause substantial morbidity and mortality, particularly among immunosuppressed patients, and can prove to be lethal in also healthy individuals when they get into deeper tissues.
  • If approved, olorofim will be the first of a new class of antifungal drugs.”
    Olorofim is the only antifungal medication to be awarded Breakthrough Therapy Designation by the FDA.

F2G Announces Data from Phase 2b Study at ID Week 2022 Showing Positive Therapeutic Response in Patients with Invasive Fungal Infections Treated with Olorofim

Retrieved on: 
Freitag, Oktober 21, 2022
News, European Medicines Agency, Nausea, Aspergillosis, SOC, Infection, US Foods, QIDP, Mycosis, Diarrhea, Patient, Fungus, Hematology, Standard of care, Hepatotoxicity, Mortality, Coccidioidomycosis, BID, Food, Scedosporiosis, ACM, Vomiting, DHODH, Food and Drug Administration, MD, Doctor of Philosophy, Immunosuppression, Safety, CNS, GLOBE, Goodyear F2G Corsair, Central nervous system, Antifungal, FDA, Breakthrough therapy, UZ Leuven, Pharmaceutical industry, Scopulariopsis, Overalls, Coccidioides, Aspergillus, Scedosporium

Approximately 75% of patients in this analysis had moderate to high levels of immunosuppression, with about half suffering from fungal infections due to Aspergillus.

Key Points: 
  • Approximately 75% of patients in this analysis had moderate to high levels of immunosuppression, with about half suffering from fungal infections due to Aspergillus.
  • Data came from 100 patients with proven invasive fungal infection or probable pulmonary invasive aspergillosis (IA).
  • Mortality remains unacceptably high in patients with severe and life-threatening fungal infections being treated with currently available therapies.
  • Olorofim has been granted Qualified Infectious Disease Product (QIDP) designation for invasive aspergillosis, invasive scedosporiosis, invasive lomentosporiosis, coccidioidomycosis, invasive disease due to Scopulariopsis species, and invasive fusariosis.

F2G to Present Interim Results from Phase 2B Open Label Study of Olorofim in Invasive Fungal Infections at IDWeek 2022

Retrieved on: 
Donnerstag, Oktober 13, 2022
European Medicines Agency, Immunology, Disease, G.H. Raisoni Department of Microbiology and Biotechnology, SOC, Infection, QIDP, Mycosis, Gambat Liver Transplant Unit, Patient, Hematology, Standard of care, Inhalation, Comparison, Mortality, Coccidioidomycosis, Internal medicine, IFI, Company, Department, Transplant, OLO, Safety, GLOBE, Aspergillosis, Antifungal, FDA, UZ Leuven, Human, Pharmaceutical industry, Dentistry, Scopulariopsis, Coccidioides, KU Leuven, Aspergillus

The Company will also present posters on pharmacokinetic data from Phase 1 and Phase 2B studies of olorofim antifungal therapy.

Key Points: 
  • The Company will also present posters on pharmacokinetic data from Phase 1 and Phase 2B studies of olorofim antifungal therapy.
  • Olorofim has received orphan drug status from the European Medicines Agency for the treatment of invasive aspergillosis and invasive scedosporiosis.
  • Olorofim has been granted Qualified Infectious Disease Product (QIDP) designation for invasive aspergillosis, invasive scedosporiosis, invasive lomentosporiosis, coccidioidomycosis, invasive disease due to Scopulariopsis species, and invasive fusariosis.
  • Invasive aspergillosis is a rare disease that can occur in over 10% of some high-risk immunosuppressed populations with mortality exceeding 80%.

Mazen Animal Health Reports Breakthrough in Valley Fever Vaccine Development

Retrieved on: 
Mittwoch, Oktober 10, 2018
Vaccination, Virology, Medicine, Coccidioides, Coccidioidomycosis, Microbiology, Clinical medicine, Vaccines, Influenza vaccines

ST. JOSEPH, Mo., Oct. 10, 2018 /PRNewswire/ --Mazen Animal Health, a biotechnology company focused on developing and commercializing novel maize-based vaccines and therapeutics that address unsolved challenges in animal health, announces a breakthrough in the development of a first-ever Valley fever sub-unit vaccine for companion animals.

Key Points: 
  • ST. JOSEPH, Mo., Oct. 10, 2018 /PRNewswire/ --Mazen Animal Health, a biotechnology company focused on developing and commercializing novel maize-based vaccines and therapeutics that address unsolved challenges in animal health, announces a breakthrough in the development of a first-ever Valley fever sub-unit vaccine for companion animals.
  • In mice, the vaccine was found to reduce the burden of Coccidioides, the fungus that can cause Valley fever.
  • Today, there is no vaccine for Valley fever, in part because the antigen is poorly expressed in microbial systems leading to a high cost of production.
  • "A Valley fever vaccine is a great fit with Mazen's focus on addressing unmet needs in animal health."